Literature DB >> 21402610

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Hazel B Nichols1, Amy Berrington de González, James V Lacey, Philip S Rosenberg, William F Anderson.   

Abstract

PURPOSE: Contralateral breast cancer (CBC) is the most frequent new malignancy among women diagnosed with a first breast cancer. Although temporal trends for first breast cancers have been well studied, trends for CBC are not so well established. PATIENTS AND METHODS: We examined temporal trends in CBC incidence using US Surveillance, Epidemiology, and End Results database (1975 to 2006). Data were stratified by estrogen receptor (ER) status of the first breast cancer for the available time period (1990+). We estimated the annual percent change (EAPC) in CBC rates using Poisson regression models adjusted for the age at and time since first breast cancer diagnosis.
RESULTS: Before 1985, CBC incidence rates were stable (EAPC, 0.27% per year; 95% CI, -0.4 to 0.9), after which they declined with an EAPC of -3.07% per year (95% CI, -3.5 to -2.7). From 1990 forward, the declines were restricted to CBC after an ER-positive cancer (EAPC, -3.18%; 95% CI, -4.2 to -2.2) with no clear decreases after an ER-negative cancer. Estimated current age-specific CBC rates (per 100/year) after an ER-positive first cancer were: 0.45 for first cancers diagnosed before age 30 years and 0.25 to 0.37 for age 30 years or older. Rates after an ER-negative cancer were higher: 1.26 before age 30 years, 0.85 for age 30 to 35 years, and 0.45 to 0.65 for age 40 or older.
CONCLUSION: Results show a favorable decrease of 3% per year for CBC incidence in the United States since 1985. This overall trend was driven by declining CBC rates after an ER-positive cancer, possibly because of the widespread usage of adjuvant hormone therapies, after the results of the Nolvadex Adjuvant Trial Organisation were published in 1983, and/or other adjuvant treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402610      PMCID: PMC3082975          DOI: 10.1200/JCO.2010.32.7395

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002.

Authors:  Claire F Snyder; Kevin D Frick; Melinda E Kantsiper; Kimberly S Peairs; Robert J Herbert; Amanda L Blackford; Antonio C Wolff; Craig C Earle
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

2.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Authors:  R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

4.  Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives.

Authors:  Lisbeth Bertelsen; Lene Mellemkjaer; Jane Christensen; Rajesh Rawal; Jørgen H Olsen
Journal:  Epidemiology       Date:  2009-03       Impact factor: 4.822

5.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Authors:  Raimund Jakesz; Richard Greil; Michael Gnant; Marianne Schmid; Werner Kwasny; Ernst Kubista; Brigitte Mlineritsch; Christoph Tausch; Michael Stierer; Friedrich Hofbauer; Karl Renner; Christian Dadak; Ernst Rücklinger; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

6.  Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

Authors:  J N Ingle; D Tu; J L Pater; H B Muss; S Martino; N J Robert; M J Piccart; M Castiglione; L E Shepherd; K I Pritchard; R B Livingston; N E Davidson; L Norton; E A Perez; J S Abrams; D A Cameron; M J Palmer; P E Goss
Journal:  Ann Oncol       Date:  2008-03-10       Impact factor: 32.976

7.  Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

Authors:  Tiffany H Svahn; Joyce C Niland; Robert W Carlson; Melissa E Hughes; Rebecca A Ottesen; Richard L Theriault; Stephen B Edge; Anne F Schott; Michael A Bookman; Jane C Weeks
Journal:  J Natl Compr Canc Netw       Date:  2009-02       Impact factor: 11.908

8.  Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study.

Authors:  Claire F Snyder; Kevin D Frick; Kimberly S Peairs; Melinda E Kantsiper; Robert J Herbert; Amanda L Blackford; Antonio C Wolff; Craig C Earle
Journal:  J Gen Intern Med       Date:  2009-01-21       Impact factor: 5.128

9.  Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015.

Authors:  Roberta De Angelis; Andrea Tavilla; Arduino Verdecchia; Steve Scoppa; Mark Hachey; Eric J Feuer; Angela B Mariotto
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

10.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

View more
  69 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

Review 2.  United States trends in the surgical treatment of primary breast cancer.

Authors:  Todd M Tuttle; Natasha M Rueth; Andrea Abbott; Beth A Virnig
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

3.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

Authors:  Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

4.  Immediate bilateral nipple-sparing mastectomy and implant-based breast reconstruction.

Authors:  Mark V Schaverien
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Karen Sepucha; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Meghan E Meyer; Lidia Schapira; Steven E Come; Virginia F Borges; Mehra Golshan; Eric P Winer; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2015-05-01       Impact factor: 5.344

6.  Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.

Authors:  Megan E Miller; Shirin Muhsen; Emily C Zabor; Jessica Flynn; Cristina Olcese; Dilip Giri; Kimberly J Van Zee; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2019-09-24       Impact factor: 5.344

Review 7.  Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.

Authors:  Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

8.  Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

Authors:  Shoshana M Rosenberg; Michaela S Tracy; Meghan E Meyer; Karen Sepucha; Shari Gelber; Judi Hirshfield-Bartek; Susan Troyan; Monica Morrow; Lidia Schapira; Steven E Come; Eric P Winer; Ann H Partridge
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

9.  Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.

Authors:  Chang Xia; Mary C Schroeder; Ronald J Weigel; Sonia L Sugg; Alexandra Thomas
Journal:  Ann Surg Oncol       Date:  2014-06-17       Impact factor: 5.344

10.  Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics.

Authors:  Habib Rahbar; Lucy G Hanna; Constantine Gatsonis; Mary C Mahoney; Mitchell D Schnall; Wendy B DeMartini; Constance D Lehman
Journal:  Radiology       Date:  2014-06-16       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.